NVO - Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years A Study Shows; Company Calls Data Insufficient | Benzinga
An analysis of U.S. pharmacy claims data reveals that only one in four patients prescribed Novo Nordisk A/S’s (NYSE:NVO) weight-loss drugs, Wegovy and Ozempic, continue their treatment after two years.
The data provided to Reuters highlights a significant decline in long-term adherence to these medications.
The analysis, conducted by Prime Therapeutics and Magellan Rx Management, offers a longer view of real-world usage compared to previous research, according to the exclusive Reuters report.
Also Read: Eli Lilly’s Mounjaro Outpaces Novo Nordisk’s Ozempic In Weight Loss Effectiveness, Study Shows.
Prime Therapeutics and Magellan Rx Management reviewed pharmacy and medical claims data for 3,364 patients with commercial health plans that cover GLP-1 drugs.
The study focused on patients who received new prescriptions between January and December 2021 and had a diagnosis of obesity or a BMI of 30 or higher.
The analysis excluded those using the drugs for type 2 diabetes and found that ...